Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
Nov 18, 2026, 13:34

Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH

Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article, by Stacy E. Croteau et al, published in Journal of Thrombosis and Haemostasis, adding:

“Assessment of documentation and reporting methods for annual bleeding rate in hemophilia clinical trials: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders

How comparable are bleeding outcomes across hemophilia trials?

This ISTH SSC review assessed 27 pivotal phase III publications covering factor concentrates, nonfactor therapies, and gene therapies.

Sixty-seven percent did not include a bleed-event definition, and only 17 trials (63%) incorporated annualized bleeding rate into the primary efficacy outcome.

Observation periods and reporting methods also varied.

The findings underscore the need for transparent, consistent definitions and analyses when interpreting results across therapies.”

Title: Assessment of documentation and reporting methods for annual bleeding rate in hemophilia clinical trials: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders

Authors: Stacy E. Croteau, Giancarlo Castaman, Karin Fijnvandraat, Susan Shapiro, Alok Srivastava

Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials - JTH

Stay updated on all scientific advances with Hemostasis Today.